Search results (121)
« Back to NewsCheck-list recommended to improve reporting of microscopy methods and results in malaria studies
13 January 2021
MORU Bangkok Publication Research
A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.
Susie Dunachie awarded flagship NIHR career development award
16 December 2020
Awards & Appointments MORU Bangkok
Susie Dunachie joins a prestigious group of leading health researchers in the latest cohort of NIHR Global Research Professors. These awards fund research leaders of the future to promote effective translation of research and to strengthen health, public health and care research leadership at the highest academic levels. Research conducted by Global Research Professors directly benefits people in LMICs. A Consultant in Infectious Diseases and Medical Microbiology, Susie works on the development of a vaccine to prevent death from melioidosis in people with type 2 diabetes mellitus in LMICs, and supports vaccine research in Thailand. Congratulations!
The COVID-19 vaccine: do we know enough to end the pandemic?
7 December 2020
Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.
New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria
1 December 2020
MORU Bangkok Publication Research
A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.
Applicability of COVID-19 vaccine trial results to low-and-middle-income countries
5 November 2020
In the next few months, the first Phase 3 COVID-19 vaccine trials – the majority of them in upper-middle or high-income countries and in specific target populations like young adults – will report their results. How relevant will their study results be for low-resource settings?
Congratulations new NDM professors
30 October 2020
Awards & Appointments LOMWRU MORU Bangkok
The University of Oxford has awarded CTMGH two new Professors. Elisabeth Ashley - UK-trained physician who specialises in infectious diseases and medical microbiology & virology, and Director of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) in Lao PDR since 2019, Liz is conferred the title of Professor of Tropical Medicine. Stuart Blacksell - Senior Research Scientist based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand, Stuart is conferred the title of Professor of Tropical Microbiology.
British Pharmacology Society honours Joel Tarning
28 October 2020
We are pleased to announce that Prof Joel Tarning has been awarded the biennial Grahame-Smith Prize by the British Pharmacological Society for outstanding contributions to clinical pharmacology. Joel has headed MORU's Clinical Pharmacology Department since 2012. Since then, the Department has grown into large, productive group that conducts laboratory- and computer-based pharmacology research.
Oxford Global Research
23 October 2020
COMRU MOCRU MORU Bangkok Research SMRU
Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. To showcase our global research, the University launched a Global Research Map, highlighting areas of research we are conducting overseas.
Parenting for lifelong health for young children, project led by MORU Bioethics & Engagement Amalee McCoy
14 October 2020
MORU Bangkok Public Engagement Video
The University of Oxford, MORU, the University of Cape Town, the Thai Ministry of Public Health, and UNICEF Thailand worked together to promote lifelong health and well-being, and prevent violence against children. Led by Amalee McCoy from MORU Department of Bioethics & Engagement, this project involved the cultural adaptation and testing of an evidence-based parenting intervention for low-income families with children aged 2-9 living in Udon Thani, Thailand.
MORU students Mo Yin and Myo Maung Maung Swe receive NDM awards
14 October 2020
Awards & Appointments MOCRU MORU Bangkok
MORU’s Mo Yin and MOCRU’s Myo Maung Maung Swe were awarded a prize by the NDM’s Graduate Studies Committee. Very competitive awards, the prizes are given annually to current or recently graduated students of NDM supervisors on the basis of their publication record, the impact and novelty of their research, references, and research within their department.
Large scale systematic review details causes of non-malarial febrile illnesses globally and identifies research priorities
21 September 2020
COMRU LOMWRU MORU Bangkok Publication Research
A series of articles that set out to explore the global distribution of infections that cause non-malarial febrile illness has been published in BMC Medicine. The series brings together the results of large-scale systematic reviews of the causes of fever in Africa, Latin America, and Southern and South-Eastern Asia, and has helped identify major knowledge gaps, geographical differences, priority areas for diagnostics research and development, and enabled the most comprehensive systematic review of literature to date.
Microscopy standards to harmonise methods for malaria clinical research studies
10 September 2020
MORU Bangkok Publication Research
Research Malaria Microscopy Standards (ReMMS) applicable to malaria clinical research studies have been published in Malaria Journal. The paper describes the rationale for proposed standards to prepare, stain and examine blood films for malaria parasites.
Hydroxychloroquine doses in COVID-19 prevention trials should be safe, study finds. Now let’s find out if they’re effective.
10 September 2020
COPCOV COVID-19 MORU Bangkok Research
As the world waits impatiently for a COVID-19 vaccine, an exhaustive review of hydroxychloroquine and chloroquine pharmacology suggests that the doses used in COVID-19 prevention trials are safe, say University of Oxford affiliated researchers in a study published in PLoS Medicine.
Hydroxychloroquine is being discarded prematurely in COVID-19 prevention
6 August 2020
Hydroxychloroquine could still prevent COVID-19 and save tens of thousands of lives around the world, say leading scientific researchers. While it doesn’t work in treatment of hospitalised patients, it could still prevent infections. However, fraudulent data, unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity may stop COPCOV, the only large, global clinical trial testing hydroxychloroquine in COVID-19 prevention, from ever finding out.
Drug-resistant enteric fever, antibiotics and the need for clean water
5 August 2020
Blog by Professor Christiane Dolecek. Antimicrobial resistance is a critical problem in enteric fever. Drug-resistant infections can have severe consequences, and slowing their spread requires our urgent attention. The most important intervention is to reduce the number of infections; vaccines are a critical tool, alongside surveillance and diagnosis. To achieve this control, strong partnerships between WHO, governments, NGOs, academia, private sector and communities are needed.
New Oxford academic titles for MORU colleagues
14 July 2020
Awards & Appointments COMRU LOMWRU MORU Bangkok
The results of the University of Oxford’s Recognition of Distinction exercise for Associate Professor and University Research Lecturer are in, and I am delighted to announce that the University has conferred titles on the following MORU staff:
UK regulator gives green light to clinical trial of hydroxychloroquine to prevent Covid-19 in healthcare workers
29 June 2020
The UK regulator MHRA announced on 26 June that it would again permit recruitment to the COPCOV COVID-19 prevention clinical trial. The MHRA decision came 5 weeks after it reacted immediately to the now-discredited paper published in The Lancet suggesting harms with hydroxychloroquine, and paused recruitment of UK participants. But The Lancet paper was based on fabricated data and was swiftly retracted. After this interruption, recruitment around the globe to COPCOV can now resume.
COVID-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
20 June 2020
COPCOV COVID-19 MORU Bangkok Publication
Paper by NJ White et al, PLoS Medicine, in press. Using available pharmacokinetic information from healthy volunteers, the treatment of malaria, the chronic treatment of rheumatological conditions and the toxicokinetics of chloroquine in self-poisoning, the authors predict exposures and safety margins in the high dose chloroquine and hydroxychloroquine COVID-19 prevention and treatment regimens currently under evaluation. These regimens are predicted to have reasonable safety margins. Large, well conducted randomised clinical trials with appropriate monitoring are required to determine if chloroquine and hydroxychloroquine have preventive or treatment efficacy in COVID-19 and acceptable safety. Current recommendations for their use outside of clinical trials are not justified at this time.
Major medical journals retract Covid-19 studies
9 June 2020
On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then the New England Journal of Medicine, retracted studies that were based on inaccessible data. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. MORU researchers played a key role in bringing this scandal to light, whose consequences continue to play out.
Clinical trials on hydroxychloroquine/ chloroquine in COVID-19. Statement in response to damaging recent events
5 June 2020
On 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU’s statement in response to these events.
An open letter to Richard Horton, editor of The Lancet regarding Mehra et al
29 May 2020
COPCOV COVID-19 General MORU Bangkok
The results of Mehra et al in The Lancet have had a considerable impact on public health practice and research, halted trials and caused considerable concern to participants and patients enrolled in randomised controlled trials (RCTs). This has led many researchers around the world to scrutinise in detail the publication and outline their concerns in this letter to Richard Horton, editor of The Lancet.
COPCOV study paused
26 May 2020
We received notice from the UK's MHRA (Medicines and Healthcare Products Regulatory Agency) to pause for now new enrolment into our COPCOV study. We responded promptly to the MHRA, addressing their concerns in detail and await their decision. For now, COPCOV study enrolment is paused around the globe. The safety of our participants is our first priority, as is preventing illness in front-line healthcare workers.
Global clinical trial of 40,000+ healthcare workers begins to test in UK if chloroquine and hydroxychloroquine can prevent COVID-19
21 May 2020
COPCOV COVID-19 MORU Bangkok Research
A global study to test if either chloroquine or hydroxychloroquine can prevent COVID-19 in vital frontline healthcare workers will open to UK participants at hospital sites in Brighton and Oxford today.
SEBCOV study launched today
1 May 2020
COVID-19 MORU Bangkok Research
The SEBCOV study aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing, and travel restrictions for the COVID-19 pandemic. This study is run in four countries: UK, Thailand, Italy and Malaysia.
PAL forest malaria prophylaxis study begins in Cambodia
29 April 2020
The Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.
GroupMappers create real-time COVID-19 Bangladesh dashboard
24 April 2020
The impact of COVID-19 is quite evident at present – entire countries and cities are under lockdown, offices and industries shut and academia at a standstill. However, many people in Bangladesh remain unaware or indifferent to the warnings and safety protocols that ought to be followed to stop COVID-19’s spread. Since enforcing social distancing in a densely populated country like Bangladesh is very challenging, making people aware and maintenance of hygiene are the main means to stop the spread of COVID-19.
COPCOV Covid-19 study prepares to begin participant enrolment
23 April 2020
COMRU COPCOV COVID-19 LOMWRU MORU Bangkok Research
Less than a month after it was announced, the MORU-led COPCOV study has made quick progress and expects to begin enrolling participants by the end of April.
BBC World News interviews Nick White on chloroquine and hydroxychloroquine for COVID-19: “These drugs are not harmless, they’re dangerous in over-dose.”
6 April 2020
COPCOV COVID-19 MORU Bangkok Public Engagement
There are currently no proven vaccines or drugs to prevent COVID-19. In this BBC World News interview, MORU’s Prof Sir Nick White explains why the only way to find out if chloroquine and hydroxychloriquine work against COVID-19 is via randomised, clinical trials and how the hype over chloroquine negatively affects people with lupus and rheumatoid arthritis.
COVID-19 Therapeutics Accelerator awards $20 million in initial grants to fund clinical trials
30 March 2020
COPCOV COVID-19 MORU Bangkok Research
Researchers at MORU and two institutions in the US (University of Washington and La Jolla Institute for Immunology) receive grants from the COVID-19 Therapeutics Accelerator, a large-scale initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed the development of and access to therapies for COVID-19.
Triple drug combinations effective against drug-resistant malaria
11 March 2020
MORU Bangkok Publication Research
Adding a third anti-malaria drug to current artemisinin-combination therapies (ACTs) provides effective treatment against multidrug-resistant falciparum malaria in Southeast Asia, say Oxford researchers in a study in The Lancet. Using TACTs should extend current malaria drugs so drug-resistant malaria doesn't kill millions more and derail hopes of controlling and eliminating malaria.
Art exhibition on substandard and falsified medicines comes to Bangkok
10 January 2020
MORU Bangkok Public Engagement
When we are ill, we expect our medicines to work as intended. But what if they do not contain the ingredients listed on the packaging? The Pharmacide Arts exhibition “What’s in your medicines?” showcases the original artwork of 11 South East Asian artists. The exhibition is open to the public from 26th-28th January 2020 at the Mandarin Hotel, Bangkok, from 10 am – 5 pm.
Global study highlights the extent and impact of drug-resistant enteric fever and the urgent need for new approaches
23 December 2019
MORU Bangkok Publication Research
A new study conducted by Christiane Dolecek and colleagues analysed data on antimicrobial resistance of the bacteria Salmonella Typhi and Salmonella Paratyphi, from around the globe, spanning the time from 1990 to 2018. The study highlights the impact of drug resistance and the urgent need for interventions.
Joel Tarning wins Ashford award at ASTMH 2019
22 November 2019
Awards & Appointments MORU Bangkok
Professor Joel Tarning received a Bailey K. Ashford Medal at the ASTMH 2019 Conference. The medal is awarded annually for distinguished work in tropical medicine by an early- to mid-career ASMTH member. Joel is Head of Clinical Pharmacology at MORU and his work focuses on applying pharmacokinetic-phamacodynamic modelling to optimise antimalarial drug therapies, in particular for at-risk groups such as malnourished children and pregnant women.
Congratulations new TropMed professors
9 October 2019
Awards & Appointments MORU Bangkok
Oxford Medical Sciences Divisional Panel has conferred the title of Professor on three members of our Centre. Ben Cooper - Professor of Epidemiology, Sassy Molyneux - Professor of Global Health and Piero Olliaro - Professor of Poverty Related Infectious Diseases were awarded these titles in recognition of their distinction in their respective fields and contributions to the research, teaching and administration of the Department and we congratulate them on their success!
New research supports co-administration of primaquine with artemisinin-based combination therapies for P. vivax malaria
8 October 2019
MORU Bangkok Publication Research
An individual patient data meta-analysis of 2,017 patients from 19 studies has found a high risk of recurrence following treatment of P. vivax malaria with artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) unless they are co-administered with primaquine. The research supports recommendations that these artemisinin-based combination therapies (ACT) should be combined with primaquine.
Oxford Vice-Chancellor Louise Richardson visits MORU and SMRU
18 September 2019
MORU and SMRU were delighted and honoured to host the University of Oxford Vice-Chancellor Prof Louise Richardson and her party during her visit to Thailand on 1-4 September. Accompanying the Vice-Chancellor were Jeremy Woodall (Director of Development (Asia)), Frewyeni Kidane (Fundraiser for Southeast Asia), Cher Wu (Asia Development office) and Ed Gibbs (NDM Director of Finance and Operations).
MORU's new Critical Care Asia Network: 42 ICUs in 9 countries
18 September 2019
In partnership with the Wellcome Innovations Flagship Programme, MORU launched its Critical Care Asia Network project with its first investigators’ meeting on 19-20 Aug in Bangkok. The project will establish an Asian ICU network across 42 ICUs in nine countries and implement a setting-adapted electronic registry.
Oxford Tropical Medicine awarded two RSTMH medals
17 September 2019
Awards & Appointments General MORU Bangkok
Two researchers from the Centre for Tropical Medicine and Global Health were awarded medals by the Royal Society of Tropical Medicine and Hygiene at the 2019 European Congress on Tropical Medicine and International Health. Professor David Warrell was awarded the Sir Patrick Manson Medal, and Dr Samson Kinyanjui the Chalmers Medal.
Antimalarial treatments less effective in severely malnourished children
24 July 2019
MORU Bangkok Publication Research
MORU researchers have found that severe malnutrition is associated with lower exposure to the antimalarial drug lumefantrine in children treated with artemether-lumefantrine, the most common treatment for uncomplicated falciparum malaria. The study, which is the first to specifically address this, calls urgently for further research into optimised dosing regimens for undernourished children.
Rapidly spreading multidrug-resistant parasites render frontline malaria drug ineffective in southeast Asia
23 July 2019
MORU Bangkok Publication Research
A rapidly evolving multi-drug resistant lineage of P. falciparum malaria parasites continues to spread in South East Asia, leading to alarmingly high treatment failure rates in Cambodia, Thailand and Vietnam for DHA-piperaquine, one of the world’s most important anti-malaria drugs.